Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2012 Jul 20;14(4):R110.
doi: 10.1186/bcr3231.

Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer

Tomasz Byrski, Rebecca Dent, Pawel Blecharz, Malgorzata Foszczynska-Kloda, Jacek Gronwald, Tomasz Huzarski, Cezary Cybulski, Elzbieta Marczyk, Robert Chrzan, Andrea Eisen, Jan Lubinski, Steven A Narod
Clinical Trial

Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer

Tomasz Byrski et al. Breast Cancer Res. .

Abstract

Introduction: The purpose of this investigation was to evaluate the efficacy of cisplatin chemotherapy in BRCA1 mutation carriers with metastatic breast cancer.

Methods: In a phase II, open-label study, 20 patients with metastatic breast cancer who carried a mutation in BRCA1 were treated with cisplatin 75 mg/m2 intravenously every 3 weeks as part of a 21-day cycle for 6 cycles. Restaging studies to assess response were performed after cycles 2 and 6, and every three months thereafter.

Results: Between July 2007 and January 2009, 20 patients were enrolled. Baseline characteristics were as follows: 65% had prior adjuvant chemotherapy, 55% had prior chemotherapy for metastatic breast cancer; mean age was 48 years (ranges 32 to 70); 30% estrogen receptor (ER) or progesterone receptor (PR)+, 70% ER/PR/Human Epidermal Growth Factor Receptor 2 (HER2)- and 0% HER2+. Overall response rate was 80%; nine patients experienced a complete clinical response (45%) and seven experienced a partial response (35%). Overall survival was 80% at one year, 60% at two years and 25% at three years. Four of the 20 patients are alive four years after initiating treatment. The median time to progression was 12 months. The median survival from the start of cisplatinum treatment was 30 months. Cisplatin-related adverse events, including nausea (50%), anemia (5%) and neutropenia (35%) were mostly mild to moderate in severity.

Conclusions: This phase II study demonstrates that cisplatin chemotherapy has high activity in women with a BRCA1 mutation and metastatic breast cancer and is generally well tolerated.

Trial registration: This trial is registered retrospectively on the clinical trials website ClinicalTrials.gov. The identifier is NCT01611727.

PubMed Disclaimer

Figures

Figure 1
Figure 1
CT images of pre- and post-treatment for patient experiencing a complete response. Upper left: pre-treatment axial-mediastinal window. Upper right: post-treatment axial mediastinal window. Lower left: pre-treatment sagittal-mediastinal window. Lower right: post-treatment sagittal-mediastinal window.
Figure 2
Figure 2
Progression after initiation of cisplatin treatment. b) Survival after initiation of cisplatin treatment.
See this image and copyright information in PMC

Comment in

References

    1. Chappuis PO, Goffin J, Wong N, Perret C, Ghadirian P, Tonin PN, Foulkes WD. A significant response to neo-adjuvant chemotherapy in BRCA1/2 related breast cancer. J Med Genet. 2002;14:608–610. doi: 10.1136/jmg.39.8.608. - DOI - PMC - PubMed
    1. Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, Mierzwa T, Szwiec M, Wiśniowski R, Siolek M, Narod SA, Lubinski J. Response to neoadjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res Treat. 2008;14:289–296. doi: 10.1007/s10549-007-9600-1. - DOI - PubMed
    1. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;14:123–134. doi: 10.1056/NEJMoa0900212. - DOI - PubMed
    1. Marcus JN, Watson P, Page DL, Narod SA, Tonin P, Lenoir GM, Serova O, Lynch HT. BRCA2 hereditary breast cancer pathophenotype. Breast Cancer Res Treat. 1997;14:275–277. doi: 10.1023/A:1005830230664. - DOI - PubMed
    1. Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, Farid LM, Venter D, Antoniou A, Storger-Isser A, Smyth E, Steel CM, Haites N, Scott RJ, Goldgar D, Neuhausen S, Daly PA, Ormiston W, McManus R, Scherneck S, Ponder BA, Ford D, Peto J, Stoppa-Lyonnet D, Bignon YJ, Struewing JP, Spurr NK, Bishop DT, Klijn JG, Devilee P. et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst. 1998;14:1138–1145. doi: 10.1093/jnci/90.15.1138. - DOI - PubMed

Publication types

MeSH terms

Associated data